Semaglutide (Wegovy) vs Semaglutide (Wegovy tablets)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: December 2026 · NCT05173714 (registry estimate)
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Semaglutide (Wegovy tablets)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Semaglutide (Wegovy) | Semaglutide (Wegovy tablets) |
|---|---|---|
| Body weight, % change | -19.5% vs -3.8%−15.7 vs placeboNCT0564670628 other results
| -14.9% vs -1.5%−13.4 vs placeboNCT051320882 other results
|
| Weight loss of 5% or more | 87% vs 29.2%+57.8 vs placeboNCT050647351 other result
| —Not posted · NCT05890976 |
| Weight loss of 10% or more | 70.4% vs 9.2%+61.2 vs placeboNCT050647359 other results
| —Not posted · NCT05890976 |
| Waist circumference, change (cm) | -7.5 vs -1−6.5 vs placeboNCT0357459735 other results
| -11.2 vs -1.4−9.8 vs placeboNCT051320882 other results
|
Body weight, % change
- Semaglutide (Wegovy)
- -19.5% vs -3.8%−15.7 vs placeboNCT05646706
28 other results
- -14.2% vs -2.5% NCT05064735
- -13.4% vs -1.9% NCT03811574
- -14.4% vs -2.7% NCT05040971
- -13.9% vs -2.5% NCT04788511
- -12.2% vs -2.2% NCT06041217
- -12.5% vs -3.6% NCT04251156
- -9.9% vs -1.9% NCT03811574
- -16.4% vs -2.6% NCT04998136
- -16.4% vs -2.7% NCT04998136
- -16.4% vs -6.4% NCT04074161
- -9.4% vs -0.9% NCT03574597
- -17.7% vs -5.4% NCT03548987
- -7.8% vs -6% NCT03611582
- -14.8% vs 2.3% NCT04102189
- -16.4% vs -1.6% NCT04074161
- -15.8% vs -3.3% NCT03693430
- -9.9% vs -7.2% NCT03552757
- -19.5% vs -16.4% NCT05646706
- -5.5% vs -3.1% NCT04969939
- -13.8% vs -2.3% NCT02453711
- -16.3% vs -2.3% NCT02453711
- -11.2% vs -2.3% NCT02453711
- -11.4% vs -2.3% NCT02453711
- -11.6% vs -2.3% NCT02453711
- -8.6% vs -2.3% NCT02453711
- -6.0% vs -2.3% NCT02453711
- -4.5% vs -0.2% NCT04779697
- -13.6% vs -7.4% NCT05579249
- Semaglutide (Wegovy tablets)
- -14.9% vs -1.5%−13.4 vs placeboNCT05132088
2 other results
- -15.8% vs -2.2% NCT05035095
- -14.4% vs -2.5% NCT05564117
Weight loss of 5% or more
- Semaglutide (Wegovy)
- 87% vs 29.2%+57.8 vs placeboNCT05064735
1 other result
- 72.5% vs 17.7% NCT04102189
- Semaglutide (Wegovy tablets)
- —Not posted · NCT05890976
Weight loss of 10% or more
- Semaglutide (Wegovy)
- 70.4% vs 9.2%+61.2 vs placeboNCT05064735
9 other results
- 61.8% vs 8.1% NCT04102189
- 65.9% vs 9.5% NCT04788511
- 64.6% vs 10.1% NCT02453711
- 71.9% vs 10.1% NCT02453711
- 57.8% vs 10.1% NCT02453711
- 58.5% vs 10.1% NCT02453711
- 56.0% vs 10.1% NCT02453711
- 36.6% vs 10.1% NCT02453711
- 18.9% vs 10.1% NCT02453711
- Semaglutide (Wegovy tablets)
- —Not posted · NCT05890976
Waist circumference, change (cm)
- Semaglutide (Wegovy)
- -7.5 vs -1−6.5 vs placeboNCT03574597
35 other results
- -14.1 vs -4.4 NCT03548935
- -6.9 vs 3.2 NCT03548987
- -9.7 vs -4.3 NCT03552757
- -15.2 vs -6.1 NCT03611582
- -18 vs -5.6 NCT05646706
- -13.3 vs -5.9 NCT05064735
- -12.7 vs -0.5 NCT04102189
- -13.6 vs -2 NCT04074161
- -11.2 vs -1.8 NCT03811574
- -10.2 vs -1.9 NCT03811574
- -11.6 vs -2.8 NCT05040971
- -12 vs -2.8 NCT04788511
- -14.3 vs -4.5 NCT03693430
- -9.1 vs -2.4 NCT06041217
- -11.1 vs -3.8 NCT04251156
- -15.2 vs -4.3 NCT03693430
- -7.8 vs -1.8 NCT03811574
- -7.6 vs -1.9 NCT03811574
- -12 vs -3 NCT04998136
- -4.8 vs -2.7 NCT04969939
- -12.3 vs -3.5 NCT02453711
- -14.9 vs -3.5 NCT02453711
- -10.9 vs -3.5 NCT02453711
- -11.1 vs -3.5 NCT02453711
- -11.0 vs -3.5 NCT02453711
- -8.8 vs -3.5 NCT02453711
- -6.1 vs -3.5 NCT02453711
- -18.2 vs -14.7 NCT05616013
- -21.3 vs -14.7 NCT05616013
- -15.8 vs -13.6 NCT05616013
- -19.0 vs -13.6 NCT05616013
- -15.6 vs -14.7 NCT05616013
- -18.1 vs -14.7 NCT05616013
- -14.6 vs -13.6 NCT05616013
- -16.6 vs -13.6 NCT05616013
- Semaglutide (Wegovy tablets)
- -11.2 vs -1.4−9.8 vs placeboNCT05132088
2 other results
- -13.4 vs -2.8 NCT05035095
- -12.9 vs -3.1 NCT05564117
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
25 other shared endpoints and safety
Coverage. Semaglutide (Wegovy): 29 of 29 rows · Semaglutide (Wegovy tablets): 28 of 29 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Wegovy) Rows use multiple source trials | Semaglutide (Wegovy tablets) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -5.8 vs -1 placebo kg @ 68wk2.4 mg weeklya,b NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials-2.7 vs 2 placebo kg @ 68wk2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 -3.6 vs -1.2 placebo kg @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 -6.2 vs -2.2 placebo kg @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -5.9 vs 0 placebo kg @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence -3.1 vs -0.6 placebo kg @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -4.3 vs -0.6 placebo kg @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -4.89 vs -0.47 placebo kg @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial-5.9 vs -0.9 placebo kg @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| CRP Change mg/dL absolute change · ratio | 0.38 vs 0.89 placebo ratio @ 72wk7.2 mga,b,c NCT05646706 · Phase 3 · registry result, not featured evidence | 0.42 vs 0.85 placebo ratio @ 68wk50 mg once dailya,b,c NCT05035095 · Phase 3 · registry result, not featured evidence |
| DBP absolute change · mmHg | -2 vs -1 placebo mmHg @ 68wk2.4 mgd,b NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 5 other source trials-3 vs -1 placebo mmHg @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -2 vs -1 placebo mmHg @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence -5 vs 1 placebo mmHg @ 68wk2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence -5 vs -3 placebo mmHg @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -5 vs -3 placebo mmHg @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -6 vs -1 placebo mmHg @ 68wk50 mgd,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial-2 vs -1 placebo mmHg @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L | -0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mge,a,b,f NCT03693430 · Phase 3 · registry result, not featured evidence show 1 more dose-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted | -0.41 vs 0.01 placebo mmol/L @ 64wk*25 mg once dailya,b,f NCT05564117 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.3 mg/dL as posted |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -9.2 vs -0.4 placebo mg @ 68wk2.4 mg weeklya,b NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 4 other source trials-37.9 vs -2.3 placebo mg @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 -7.3 vs -1.1 placebo mg @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -18.3 vs 1.7 placebo mg @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -19.3 vs 1.7 placebo mg @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -10.3 vs -1.8 placebo mg @ 68wk50 mg once dailya,b NCT05035095 · Phase 3 · registry result, not featured evidence |
| Fasting Serum Insulin absolute change · ratio | 0.68 vs 0.84 placebo ratio @ 68wk2.4 mga,b NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 | 0.67 vs 0.94 placebo ratio @ 68wk50 mg once dailya,b NCT05035095 · Phase 3 · registry result, not featured evidence |
| Free Fatty Acids absolute change · ratio | 0.86 vs 1.08 placebo ratio @ 68wk2.4 mga,b NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 2 other source trials1.04 vs 1.28 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.96 vs 1.28 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 0.87 vs 1 placebo ratio @ 68wk50 mg once dailya,b NCT05035095 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points | -0.5% (n=1197) vs -0.2% (n=563) placebo @ 68wk2.4 mg weeklya,b NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials-0.2% (n=515) vs 0.1% (n=246) placebo @ 68wk2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 -1.7% (n=381) vs -0.3% (n=374) placebo @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 -0.5% (n=369) vs -0.3% (n=184) placebo @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -0.4% (n=126) vs -0.1% (n=59) placebo @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence -0.9% (n=98) vs 0% (n=100) placebo @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -1% (n=193) vs 0% (n=100) placebo @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -0.8% (n=126) vs 0% (n=64) placebo @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial-0.2% (n=311) vs 0.1% (n=286) placebo @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| HDL-C absolute change · ratio | 1.18 vs 1.18 placebo ratio @ 68wk2.4 mga,b NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials1.07 vs 1.04 placebo ratio @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 1.06 vs 1.05 placebo ratio @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 1.08 vs 1.03 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 1.08 vs 1.03 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 1.06 vs 1.06 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 1.08 vs 1.06 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 1.07 vs 1.03 placebo ratio @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial1.05 vs 1.01 placebo ratio @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| IWQOL-Lite-CT Physical Function absolute change · score | 11.4 vs 4.9 placebo score @ 68wk2.4 mgd,b NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 | 7.6 vs 1.9 placebo score @ 68wk50 mgd,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial14.5 vs 5 placebo score @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| IWQOL-Lite-CT Physical Function responder rate · % of participants | 25.5% (n=192) vs 11% (n=100) placebo @ 68wk*2.4 mge,a,b NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 49 Participants as posted show 1 more dose19.4% (n=98) vs 11% (n=100) placebo @ 68wk*1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted | 50% (n=298) vs 31.3% (n=278) placebo @ 68wk*50 mg once dailya,b Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted |
| LDL-C absolute change · ratio | 1.01 vs 1.07 placebo ratio @ 68wk2.4 mga,b NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials1 vs 1 placebo ratio @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 0.96 vs 1.01 placebo ratio @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 0.91 vs 0.96 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.91 vs 0.96 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.9 vs 0.95 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.86 vs 0.95 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 0.89 vs 1.02 placebo ratio @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial0.98 vs 1.03 placebo ratio @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -7 vs -1 placebo mmHg @ 68wk2.4 mg weeklya,b NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 7 other source trials0 vs 5 placebo mmHg @ 68wk2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 -4 vs 0 placebo mmHg @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 -6 vs -2 placebo mmHg @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -3 vs -1 placebo mmHg @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence -7 vs 5 placebo mmHg @ 68wk2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence -12 vs -5 placebo mmHg @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -11 vs -5 placebo mmHg @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -11 vs -2 placebo mmHg @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial-7 vs -1 placebo mmHg @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| SF-36 Physical Functioning absolute change · score | 2.8 vs 0.8 placebo score @ 68wk2.4 mgd,b NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 1 other source trial12.7 vs 6.4 placebo score @ 68wk2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence | 2.4 vs 0 placebo score @ 68wk50 mg once dailyd,b NCT05035095 · Phase 3 · registry result, not featured evidence |
| SF-36 Physical Functioning responder rate · % of participants | 22.4% (n=192) vs 13% (n=100) placebo @ 68wk*2.4 mge,a,b NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted show 1 more dose19.4% (n=98) vs 13% (n=100) placebo @ 68wk*1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted | 37.3% (n=303) vs 20% (n=280) placebo @ 68wk*50 mg once dailya,b Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 113 Participants as posted |
| Total Cholesterol absolute change · ratio | 1.05 vs 1.11 placebo ratio @ 68wk2.4 mga,b NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials0.99 vs 1 placebo ratio @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 0.96 vs 1.01 placebo ratio @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 0.92 vs 0.98 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.92 vs 0.98 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.93 vs 1 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.91 vs 1 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 0.92 vs 1.02 placebo ratio @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial0.97 vs 1.01 placebo ratio @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Triglycerides absolute change · ratio | 0.94 vs 1.12 placebo ratio @ 68wk2.4 mga,b NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials0.79 vs 0.92 placebo ratio @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 0.77 vs 0.91 placebo ratio @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 0.71 vs 1.04 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.71 vs 1.04 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.78 vs 1.05 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.79 vs 1.05 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 0.73 vs 0.99 placebo ratio @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| VAT Change Cm2 absolute change · cm | -67.4 vs -13.8 placebo cm @ 68wk2.4 mge,a,b NCT03811574 · Phase 3 · registry result, not featured evidence show 1 more dose-41.7 vs -13.8 placebo cm @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -0.06 vs 0.02 placebo cm @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence |
| Visceral Fat percent change · % of baseline | -41% (n=86) vs -7.1% (n=43) placebo @ 68wk2.4 mge,a,b NCT03811574 · Phase 3 · registry result, not featured evidence show 1 more dose-22.3% (n=45) vs -7.1% (n=43) placebo @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -35.1% (n=50) vs 0.6% (n=20) placebo @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence |
| VLDL-C absolute change · ratio | 0.94 vs 1.12 placebo ratio @ 68wk2.4 mga,b NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 6 other source trials0.8 vs 0.92 placebo ratio @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 0.77 vs 0.91 placebo ratio @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 0.71 vs 1.03 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.71 vs 1.03 placebo ratio @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 0.79 vs 1.05 placebo ratio @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 0.79 vs 1.05 placebo ratio @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | 0.74 vs 0.99 placebo ratio @ 68wk50 mga,b NCT05132088 · Phase 3 · registry result, not featured evidence 1 other source trial0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg | -16.1 vs -2.9 placebo kg @ 68wk2.4 mg weeklya,b NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 7 other source trials-7.5 vs 5.7 placebo kg @ 68wk2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 -9.9 vs -3.4 placebo kg @ 68wk2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 -17.5 vs -6.2 placebo kg @ 68wk2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 -15.7 vs 2.3 placebo kg @ 68wk2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence -15.8 vs -1.4 placebo kg @ 68wk2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence -8.3 vs -1.7 placebo kg @ 68wk1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence -11.3 vs -1.7 placebo kg @ 68wk2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence | -16.1 vs -2.4 placebo kg @ 68wk50 mg once dailya,b NCT05035095 · Phase 3 · registry result, not featured evidence |
| Weight Loss 10% event count · % of participants | 69.1% (n=1212) vs 12% (n=577) placebo @ 68wk*2.4 mg weeklya,b Yes NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 838 Participants as posted 6 other source trials79% (n=520) vs 20.4% (n=250) placebo @ 68wk*2.4 mg Yes NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 411 Participants as posted 45.6% (n=388) vs 8.2% (n=376) placebo @ 68wk*2.4 mg Yes NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 177 Participants as posted 75.3% (n=373) vs 27% (n=189) placebo @ 68wk*2.4 mg Yes NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 281 Participants as posted 70.9% (n=117) vs 15.4% (n=78) placebo @ 68wk*2.4 mg Yes NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted 41.8% (n=98) vs 5% (n=100) placebo @ 68wk*1.7 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted 60.6% (n=193) vs 5% (n=100) placebo @ 68wk*2.4 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 117 Participants as posted | 65.4% (n=127) vs 9.4% (n=64) placebo @ 68wk*50 mga,b Yes NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted 1 other source trial69.4% (n=317) vs 11.9% (n=295) placebo @ 68wk*50 mg once daily Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 220 Participants as posted |
| Weight Loss 15% event count · % of participants | 50.5% (n=1212) vs 4.9% (n=577) placebo @ 68wk*2.4 mg weeklya,b Yes NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 612 Participants as posted 6 other source trials63.7% (n=520) vs 9.2% (n=250) placebo @ 68wk*2.4 mg Yes NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 331 Participants as posted 25.8% (n=388) vs 3.2% (n=376) placebo @ 68wk*2.4 mg Yes NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 100 Participants as posted 55.8% (n=373) vs 13.2% (n=189) placebo @ 68wk*2.4 mg Yes NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 208 Participants as posted 55.6% (n=117) vs 6.4% (n=78) placebo @ 68wk*2.4 mg Yes NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 65 Participants as posted 24.5% (n=98) vs 3% (n=100) placebo @ 68wk*1.7 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted 40.9% (n=193) vs 3% (n=100) placebo @ 68wk*2.4 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 79 Participants as posted | 47.2% (n=127) vs 0% (n=64) placebo @ 68wk*50 mga,b Yes NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 60 Participants as posted 1 other source trial53.6% (n=317) vs 5.8% (n=295) placebo @ 68wk*50 mg once daily Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 170 Participants as posted |
| Weight Loss 20% event count · % of participants | 32% (n=1212) vs 1.7% (n=577) placebo @ 68wk*2.4 mg weeklya,b Yes NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 388 Participants as posted 5 other source trials13.1% (n=388) vs 1.6% (n=376) placebo @ 68wk*2.4 mg Yes NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 51 Participants as posted 35.7% (n=373) vs 3.7% (n=189) placebo @ 68wk*2.4 mg Yes NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 133 Participants as posted 38.5% (n=117) vs 2.6% (n=78) placebo @ 68wk*2.4 mg Yes NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted 11.2% (n=98) vs 2% (n=100) placebo @ 68wk*1.7 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted 19.7% (n=193) vs 2% (n=100) placebo @ 68wk*2.4 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted | 32.3% (n=127) vs 0% (n=64) placebo @ 68wk*50 mga,b Yes NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted 1 other source trial33.8% (n=317) vs 2.7% (n=295) placebo @ 68wk*50 mg once daily Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted |
| Weight Loss 5% event count · % of participants | 88.7% (n=520) vs 47.6% (n=250) placebo @ 68wk*2.4 mga,b Yes NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 461 Participants as posted 3 other source trials68.8% (n=388) vs 57.1% (n=380) Semaglutide 1.0 mg @ 68wk*2.4 mg Yes NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted 72.4% (n=98) vs 21% (n=100) placebo @ 68wk*1.7 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 71 Participants as posted 82.9% (n=193) vs 21% (n=100) placebo @ 68wk*2.4 mg Yes NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 160 Participants as posted | 84.3% (n=127) vs 17.2% (n=64) placebo @ 68wk*50 mga,b Yes NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted 1 other source trial84.9% (n=317) vs 25.8% (n=295) placebo @ 68wk*50 mg once daily Yes NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 269 Participants as posted |
| Dropout rate | —2.4 mg weeklyg NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results5.1%2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 11%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 3.2%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 2.9% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 16.7%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 15.3%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 14.4%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 0%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 4.6%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 0% NCT04998136 · Phase 3 · registry result, not featured evidence 9.2%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 7.2%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 2.7%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 1.5%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 4.8%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 2.6%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 2%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 33.9%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 38.6%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 50%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 37.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5% NCT05302596 · Phase 2 · registry result, not featured evidence 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.9%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 8.7%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.9%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.7%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.4% NCT04779697 · Phase 1 · registry result, not featured evidence | 4.4%25 mg once dailyh NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results3%50 mg NCT05132088 · Phase 3 · registry result, not featured evidence 4.2%50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —2.4 mg weeklyg NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 5.3%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 — NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 6.4%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 —Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence —2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence — NCT04998136 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence —1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 1.8%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.3%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 5.4%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 — NCT05302596 · Phase 2 · registry result, not featured evidence —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence — NCT04779697 · Phase 1 · registry result, not featured evidence | —25 mg once dailyh NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results—50 mg NCT05132088 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.8%2.4 mg weeklyg NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 7.7%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 9.9%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 33.4% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 9.1%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 4.2%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination 0%Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 1.2%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence 8.1%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 7.3%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 12.9% NCT04998136 · Phase 3 · registry result, not featured evidence 10%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 8.7%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 13.3%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence 5.6%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 11.3%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 5%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 7%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.7%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 0% NCT05302596 · Phase 2 · registry result, not featured evidence 12.5%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 4.3%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 12.7%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 5.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 4.9%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 7.8%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 12.6%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.1% NCT04779697 · Phase 1 · registry result, not featured evidence | 3.9%25 mg once dailyh NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results6%50 mg NCT05132088 · Phase 3 · registry result, not featured evidence 9.6%50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 2.4 mg weeklyg nausea 44.1% (placebo 17.4%) diarrhoea 31.5% (placebo 15.9%) vomiting 24.6% (placebo 6.6%) NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results2.4 mg diarrhoea 14.4% (placebo 7.1%) nausea 14% (placebo 4.9%) constipation 11.6% (placebo 6%) NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 33.5% (placebo 9.2%) diarrhoea 21.3% (placebo 11.9%) vomiting 21.3% (placebo 2.7%) NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 covid-19 20.3% (placebo 20.3%) nausea 18.1% (placebo 3.8%) diarrhoea 10.6% (placebo 4%) NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 58.2% (placebo 22.1%) constipation 36.9% (placebo 24.5%) diarrhoea 36.1% (placebo 22.1%) NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 nausea 73.6% (placebo 25%) constipation 52.8% (placebo 16.7%) diarrhea 37.5% (placebo 22.9%) NCT05548647 · Phase 4 · registry result, not featured evidence · combination diarrhea 20% (placebo 22.9%) constipation 10% (placebo 16.7%) eructation 10% (placebo 6.3%) NCT05548647 · Phase 4 · registry result, not featured evidence 2.4 mg decreased appetite 19.3% (placebo 2.5%) diarrhoea 18.6% (placebo 7.4%) nausea 18% (placebo 2.5%) NCT06041217 · Phase 3 · registry result, not featured evidence 7.2 mg nausea 43.7% (placebo 13.4%) diarrhoea 27.3% (placebo 12.9%) vomiting 24.8% (placebo 7%) NCT05646706 · Phase 3 · registry result, not featured evidence nausea 37.6% (placebo 14.3%) diarrhoea 27.7% (placebo 6.1%) constipation 21.8% (placebo 16.3%) NCT04998136 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 21.9% (placebo 8.9%) covid-19 18.6% (placebo 22.2%) constipation 11.9% (placebo 5.2%) NCT05064735 · Phase 3 · registry result, not featured evidence 2.4 mg covid-19 34.8% (placebo 30.4%) nausea 29% (placebo 4.3%) constipation 18.1% (placebo 0%) NCT05040971 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 17.1% (placebo 2.6%) covid-19 13.7% (placebo 15.4%) diarrhoea 9.1% (placebo 3.8%) NCT04788511 · Phase 3 · registry result, not featured evidence 2.4 mg diarrhoea 26.1% (placebo 10.3%) nausea 24.1% (placebo 7.1%) upper respiratory tract infection 20.5% (placebo 20.6%) NCT04251156 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 42.1% (placebo 17.9%) vomiting 36.1% (placebo 10.4%) diarrhoea 21.8% (placebo 19.4%) NCT04102189 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 61.1% (placebo 22.4%) constipation 38.9% (placebo 23.5%) diarrhoea 27.8% (placebo 25.9%) NCT04074161 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 53.3% (placebo 21.7%) diarrhoea 34.9% (placebo 23.7%) constipation 30.9% (placebo 11.2%) NCT03693430 · Phase 3 · registry result, not featured evidence 2.4 mg nasopharyngitis 26.6% (placebo 17.8%) constipation 26.1% (placebo 3%) nausea 17.6% (placebo 4%) NCT03811574 · Phase 3 · registry result, not featured evidence 1.7 mg nasopharyngitis 24% (placebo 17.8%) diarrhoea 22% (placebo 5.9%) constipation 19% (placebo 3%) NCT03811574 · Phase 3 · registry result, not featured evidence 30 mg/kg + 1.0 mg muscle spasms 64.3% acne 55.4% diarrhoea 44.6% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 30 mg/kg + 2.4 mg muscle spasms 63.6% acne 52.7% diarrhoea 49.1% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 1.0 mg muscle spasms 57.1% diarrhoea 48.2% acne 42.9% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 2.4 mg muscle spasms 65.5% nausea 61.8% diarrhoea 52.7% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 gastrointestinal side effects: constipation 57.1% gi side effects: nausea 28.6% gi side effects: vomiting 14.3% NCT05302596 · Phase 2 · registry result, not featured evidence 2.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 87.5% (placebo 12.5%) vomiting 75% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2.0 mg + 2.4 mg nausea 62.5% (placebo 12.5%) constipation 50% (placebo 0%) vomiting 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 50% (placebo 12.5%) abdominal pain 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg nausea 44.7% (placebo 12.5%) vomiting 31.9% (placebo 0%) constipation 25.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0.4 mg nausea 48% (placebo 17.6%) diarrhoea 37.3% (placebo 11.8%) constipation 23.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.4 mg (Fast Escalation) nausea 48.5% (placebo 17.6%) constipation 28.2% (placebo 4.4%) diarrhoea 27.2% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg nausea 41.7% (placebo 17.6%) diarrhoea 26.2% (placebo 11.8%) constipation 17.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg (Fast Escalation) nausea 53.9% (placebo 17.6%) diarrhoea 27.5% (placebo 11.8%) vomiting 20.6% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.2 mg nausea 43.7% (placebo 17.6%) diarrhoea 34% (placebo 11.8%) constipation 25.2% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.1 mg nausea 41.2% (placebo 17.6%) diarrhoea 24.5% (placebo 11.8%) nasopharyngitis 22.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.05 mg nausea 31.1% (placebo 17.6%) diarrhoea 19.4% (placebo 11.8%) nasopharyngitis 15.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence nausea 58.3% (placebo 20.8%) abdominal pain 31.3% (placebo 20.8%) diarrhea 29.2% (placebo 10.4%) NCT04779697 · Phase 1 · registry result, not featured evidence | 25 mg once dailyh nausea 46.6% (placebo 18.6%) vomiting 30.9% (placebo 5.9%) nasopharyngitis 21.1% (placebo 26.5%) NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results50 mg covid-19 30.6% (placebo 33.3%) nausea 25.4% (placebo 7.6%) constipation 20.9% (placebo 9.1%) NCT05132088 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 51.8% (placebo 15.3%) covid-19 35.6% (placebo 34.5%) constipation 27.5% (placebo 15%) NCT05035095 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 72 weeks versus 68 weeks.
- dPopulation context differs: registered conditions differ.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 104 weeks versus 64 weeks.
- gPopulation comparability has not been reviewed for 30 of these studies.
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Wegovy)
show 3 more results
show 3 more results
show 2 more results
+ 119 further endpoints in the CSV export.
Semaglutide (Wegovy tablets)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Semaglutide (Wegovy)'s landscape · Semaglutide (Wegovy tablets)'s landscape